# Table of Contents

Message from our Chief Executive Officer  

Mirati at a Glance  

Our Approach to Sustainability  

People  

Patients and Access to Medicine  

Safety and Quality  

Environment  

Integrity and Ethics  

Appendix
Message from our Chief Executive Officer

Dear Mirati Stakeholders:

We are thrilled to share Mirati’s second annual Corporate Sustainability Report. This report highlights our commitment to adhering to and advancing practices rooted in positive corporate citizenship. In this report, we share our efforts and successes, as well as opportunities for continued prioritization of environmental, social and governance (ESG) principles.

Unified for patients, we are on a mission to discover, design and deliver breakthrough therapies to transform the lives of people living with cancer and the lives of their loved ones. We are committed to achieving this mission thoughtfully and with a focus on sustainability.

In 2022, we progressed from discovering and developing innovative cancer treatments to now delivering them to the patients who can benefit from them. This transformation allows us to directly and meaningfully impact the lives of people living with cancer. As we evolve our business, we recognize our impact can and must go beyond the walls in which we operate and the medicines we deliver. We have a responsibility to serve the communities in which we live and work.

This report showcases our commitment and efforts to create positive impact for our stakeholders. We have a passion for making a difference—in the lives of people with cancer and in the communities where we live and work. We strive to foster a workplace environment that encourages and rewards making an impact in this important and unique work. We hold ourselves to the highest ethical and operational standards, and we continue to make the investments required to meet or exceed those standards every day.

We recognize we are at the beginning stages of this important work. While we are proud of the progress we have made on ESG priorities, we look with excitement to the impact our commitment will have on communities and stakeholders in years to come. Thank you for being part of our journey.

Sincerely,

David Meek
Mirati at a Glance

Mission and Values

- Our mission is to discover, design and deliver breakthrough therapies to transform the lives of people living with cancer and their loved ones.
- Unified for patients, our vision is to unlock the science behind the promise of a life beyond cancer.
- Our passionate team is deeply motivated to participate in work that is both important and unique. Urgency, open-mindedness, accountability and collaboration are foundational principles that govern the way we work.

Our Purpose

At Mirati, we are relentlessly focused on developing first-in-class and best-in-class targeted therapies to meaningfully impact the lives of people with cancer.

By using our expanding discovery and translational research capabilities, industry collaborations and academic and community-based insight, our team of leading scientists are investigating tangible next-generation targeted cancer therapies.

Learn more about our mission, vision and values on Mirati.com/about.

KRAZATI™ (adagrasib) became our first approved drug in December 2022. It is indicated for the treatment of adult patients with KRAS\(^{G12C}\)-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA-approved test, who have received at least one prior systemic therapy.

Rapidly pushing forward to find meaningful breakthroughs and targeted solutions for
- RAS mutant cancers
- Checkpoint inhibitor resistance
- Other genetic and immunological drivers of cancer
Our Approach to Sustainability

At Mirati, we are committed to operating responsibly to cultivate a sustainable business that benefits people living with cancer, employees, communities and investors. We strive to develop novel targeted therapies for people living with cancer; to foster a culture of inclusion, collaboration and innovation; and to always operate with integrity.

Mirati’s Board of Directors (BoD) takes an active role in corporate sustainability, especially in conjunction with the Company’s overall business strategy and risk management. Specifically, the Nomination and Corporate Governance committee of the BoD oversees Mirati’s environmental, social and governance efforts. The Audit Committee oversees the risk factors disclosed in our Annual Report.

Our Executive Leadership Team (ELT), including our CEO, is subject to oversight by our BoD, and structures, monitors and adjusts corporate sustainability-related efforts in a manner that is consistent with our core values and in a manner that best serves the interests of Mirati and our stakeholders. We are guided by our stakeholders and third-party frameworks, including the Sustainability Accounting Standards Board (SASB) Biotechnology & Pharmaceuticals Standard and the Task Force on Climate-related Financial Disclosures (TCFD).
Materiality and Stakeholders Summary

An important component of developing our 2022 Corporate Sustainability Report was to perform a materiality assessment to identify the key ESG issues that are most important to our stakeholders. We consider a wide range of stakeholders to influence our environmental, social and governance strategy.

About This Report

This report provides relevant information to showcase our commitment to corporate sustainability. It provides an overview of our governance, oversight, policies, programs, performance, investments and resources.

Our ESG disclosures are managed by a cross-functional internal team consisting of senior leaders from various groups within the organization. The ongoing goal of this team is to identify material sustainability topics and establish a corresponding sustainability reporting framework. The committee relies on shareholders’ feedback, sustainability frameworks and guidelines such as those published by SASB and TCFD. In addition, we use external peer benchmarking and ESG data providers’ scoring methodologies to identify new areas of focus and opportunities. These insights, along with contributions from our management team, inform our materiality framework and help us identify relevant topics for disclosure. We are committed to incorporating these material issues into our business operations, to focusing on the topics that matter most to our business and stakeholders, and to continuously evaluate our sustainability issues for the future.

Stakeholder Groups

- Patients
- Physicians
- Employees
- Investors
- Suppliers
- Healthcare organizations
- Industry leaders
- The local communities where we operate
- Patient families
- Caregivers
People

At Mirati, we work relentlessly to develop transformative medicines and restore hope for people living with cancer. These ambitious goals would not be possible without our passionate, talented and innovative team. To succeed in our mission, we understand the importance of supporting the well-being; equitable, respectful treatment; and professional development of our employees. Additionally, supporting the communities where our employees live and work is central to our mission.

Diversity, Equity and Inclusion (DE&I)

We believe diverse professional experiences and an inclusive culture can drive better outcomes for patients. We strive to create a sense of belonging, and we continuously seek to foster a culture of diversity, equity and inclusion.

Our DE&I program, which was initiated in 2021, is led by our Chief Financial Officer and overseen by our DE&I Committee, which is made up of cross-functional representatives from across the enterprise. Our efforts are periodically presented to the BoD.

In 2022, we surveyed all employees to inform the Company’s DE&I objectives and future employee training. We are proud to have received improved scores on all items compared to the year prior, with 88% of employees agreeing or strongly agreeing that people with different backgrounds are treated with respect. As a result of this survey, we have identified opportunities where we can further enhance our DE&I efforts. Additionally, we recently assessed Mirati’s performance across DE&I metrics. To address the feedback and findings, and to further our commitment to foster diversity, we are actively working with a third-party to develop Mirati’s DE&I Project Roadmap, overseen by our DE&I Committee. As part of developing our DE&I strategy, we developed three pillars to serve as the foundation for achieving a fair and equitable environment where all Mirati employees can thrive: People, Culture and Community. The DE&I pillars are aligned to focus on key areas and goals in order to drive a positive impact for our employees and our business.

We actively integrate workforce diversity into several of our employee initiatives.

- For 2023, our corporate goals include progressing several DE&I initiatives, which demonstrates our commitment to maintaining a best-in-class corporate culture centered around DE&I
- To better reach diverse candidates in our recruiting, we use third-party Booleans to source underrepresented populations. Additionally, we use a third-party gender language decoder before any job posting goes live to ensure that it is free from gender bias
- In 2023, we plan to deploy learning initiatives centered around our DE&I objectives, such as mandatory unconscious bias training, to drive further progress throughout the organization
- To ensure employees are paid equitably across the organization without bias toward race, ethnicity, age, and gender, we periodically conduct compensation audits
To sustain our success, we embrace diverse perspectives and lived experiences (as of November 1, 2022).*

### Age

- **Generation Z**: 1.5%
- **Baby Boomers**: 10.8%
- **Generation X**: 52.5%
- **Millennials**: 35.2%

### Gender

- **Overall Company**:
  - Male: 53.7%
  - Female: 46.3%

### Ethnicity

- **White**: 54.2%
- **Decline to Disclose**: 6.2%
- **Native Hawaiian or Pacific Islander**: 0.7%
- **Two or More Races**: 3.3%
- **Black**: 4.6%
- **Hispanic**: 6.7%
- **Asian**: 24.4%

*Demographics are not inclusive of Mirati’s European employees.
Recruitment, Engagement and Retention

We know that our highly qualified and experienced team is critical to our success. We are committed to fostering a workplace environment that attracts and retains the best people. Our passionate team is deeply motivated to participate in work that is both important and unique.

Biannually, Mirati’s Human Resources team partners with leaders to determine the skills we need to develop in our current employees and to identify the talent we need to hire. We also partner with various organizations, including Partners in College Success (PiCS), San Diego Squared, Historically Black Colleges and Universities Speaker Series, Athena by Women in STEM, Women of Color in Pharma and the Biocom California Institute, to create targeted recruitment programs that include those of diverse backgrounds.

We believe in a Total Rewards experience that enables our employees to save, perform and grow for today and their future.

At Mirati, we are proud to offer our competitive benefits package that is available from the first day of employment to all employees who work 30 hours or more. In addition to our best-in-class benefits, employees are eligible for enrollment in the PeopleFuel training program from The Energy Project. The program is designed to help improve physical energy, increase emotional resilience and strengthen sense of purpose to support employee well-being and work-life balance.

We have an employee stock purchase plan (ESPP) available to all U.S. employees and are excited to announce that we are launching our ESPP in the EU in 2023.

Additional benefits available to employees include:

- Equity grants, such as stock options/RSUs and performance-based bonuses for all employees except those on commission plans
- Recognition awards
- Retirement 401(k) savings plan, with company matching contributions
- Medical, dental, vision, and other health and wellness benefits
- Employee assistance program
- Work/life balance arrangements, including core hours and flexible work arrangements
- Paid time off and holidays
- Volunteer hours
- Tuition Reimbursement Program

Training and Development

We are committed to ensuring employees have the knowledge and skills to succeed. Our internal Learning Management System tracks utilization of our training and development tools and programs. This system, along with our annual survey, helps ensure we are evolving our human capital investments to drive the best outcomes for our employees and our business.

Mirati University is a learning and development training portal available to all employees that offers independent and instructor-led courses.
We offer a series of leadership development trainings:

- Leadership Model Sessions: Interactive sessions to gain insight into leading at Mirati
- Leadership Essentials: Teaches Mirati leaders skills to make them successful leaders. We are proud that we reached our target of ~75% participation in 2021
- New People Leader Workshop: Supports new leaders in understanding Mirati’s human capital programs
- Leadership Insights: Monthly information sessions to set leadership expectations
- Development programs for individual contributors
- Career coaching and leadership development with Betterup program

Performance Reviews
All employees are eligible for annual performance reviews and mid-year check-ins with their manager.

Engagement Survey Summary
To assess our performance on metrics including mission and vision, development and empowerment, ability to adapt, as well as overall employee satisfaction, we conduct an annual company-wide, anonymous survey. Based on feedback from the three most recent surveys, we are implementing various programs to ensure we are continually enhancing life at Mirati, including programs to improve work-life balance, create meaningful work connection and provide clear direction and training on the promotion process. Mirati achieved an overall employee engagement score of 62%, which is aligned with the industry average of 63%.

Mirati is committed to fostering an open communication environment. Our Employee Handbook includes our Open Door Policy under which employees are encouraged to raise suggestions for improving the workplace, as well as procedures for raising complaints or concerns, without fear of reprisal.

Community and Philanthropy
As we work to bring life-changing medicines to people living with cancer, we are also deeply committed to giving through our Mirati Gives, Patient Advocacy and Medical Grants & Sponsorship programs.

Our approach to giving is guided by our focus on making a difference in the lives of people living with cancer and their families, as well as our employees and the communities where we live and work. We believe our employees’ skills and generosity can positively impact our communities, and that volunteerism further increases pride in what we do and connects us to one another. At Mirati, we encourage our employees to give back by providing two days of paid time off each year to volunteer.

Our charitable giving strategy focuses on:

- Science, technology, engineering and mathematics-centric education, mentorships and grants, particularly for students in underserved communities
- Community investments to address critical issues where Mirati is located, including funding for food banks
- Patient advocacy and research groups
- Diversity organizations groups

We are impacting the life of patients and their families.
Mirati Gives is the vehicle that drives corporate sponsorships, organizes the community and builds brand recognition with employees, patients and healthcare professionals (HCPs).

Impact and reach since 2021:

- Supported over $1,000,000 USD in charitable impact
- Coordinated over $150,000 USD in employee fundraising to Padres Pedal and LUNGevity Breathe Deep
- Supported over 20 organizations annually through Mirati Gives funding
- Facilitated nearly 300 employee volunteer hours for Mirati Gives supported causes
Grant Support

We also work with physicians and patient advocacy groups, and we are proud to support them in the cancer community. Examples include:

- A $4 million grant to Stand Up to Cancer® (SU2C) to develop new approaches to treat patients with KRAS mutant cancers, as a part of the SU2C Catalyst® program

- LunGevity’s “No One Missed” biomarker testing campaign, a multi-year initiative to deliver targeted education to people with lung cancer that focuses on biomarker testing and its benefits. The campaign mission is to build public awareness of comprehensive biomarker testing as a critical part of every non–small cell lung cancer (NSCLC) diagnosis and empower NSCLC patients to discuss comprehensive biomarker testing with their healthcare team

- Sponsored GO² Foundation’s ‘Advancing Inclusive Research (AIR) in the Lung Cancer Community’ project which will diversify multiple aspects of the educational information and research program to promote inclusivity among under-served/-represented populations. The project will adopt a multi-pronged approach with the goal of enhancing research participation by people with lung cancer from underrepresented groups

- Colorectal Cancer Alliance’s biomarker think tank initiative and precision medicine patient education program in 2021 brought together key leaders, clinicians, patients and researchers as a part of an advisory committee to explore barriers to biomarker literacy, access to testing and results, treatment planning and medical decision-making

- Lazarex Cancer Foundation (LCF): Be a Cancer Superhero! LCF strives to improve cancer health outcomes, clinical trial diversity and enrollment, and patient access to care. Only 6% of eligible patients participate in trials and only 5% are racial or ethnic minorities. Lazarex Cancer Foundation matches people with cancer with cutting edge treatments available in clinical trials today and reimburses the out-of-pocket expenses associated with participating in them
Mirati’s dedication to develop novel cancer therapeutics stems from our vision to unlock the science behind the promise of a life beyond cancer. We believe all people living with cancer should have access to high quality care and affordable medicines. Therefore, we are committed to ensuring that every eligible patient who could benefit from our medicine will have access regardless of their ability to pay.

We work with patients, patient advocacy groups, healthcare providers, caregivers and payers in the cancer community, and we deeply value the partnerships and collaborations we’ve made. These partnerships help us understand patient needs, particularly among high-risk or undertreated populations, and help us inform patients on access to clinical trials and approved treatment options.

Additionally, we have a dedicated team to connect and educate patients, caregivers and HCPs on reimbursement- and insurance-related matters to ensure access and affordability to our products. We are proud to have recently launched a patient services program (PSP), Mirati & Me, in connection with KRAZATI™—our first product, which was approved in December 2022. This program ensures that every person who is prescribed KRAZATI™ has access to the product through insurance, a financial assistance program provided by Mirati & Me or a combination of the two.
Financial assistance is available to eligible patients. Select examples include:

- **Free Product (Patient Assistance Program):** Program can provide KRAZATI™ at no cost, to those who meet eligibility criteria.

- **Free Trial Offer:** Helps provide opportunity for an increased clinical experience by providing a temporarily free drug utilized by HCP pharmacy with an immediate approval and reimbursement based on contracted rate.

- **Savings Card Assistance:** For commercially insured patients, the manufacturer assumes the patient's out-of-pocket cost associated with the prescribed product, to help reduce or eliminate the patient's financial burden.

- **Alternate Insurance Research:** Assists in identifying additional coverage options for eligible patients, including Low-Income Subsidy and Medicaid.

We value our partnerships that offer PSP for our patients:

---

**Mirati & Me**

The Mirati & Me program is our new comprehensive PSP, which has become available alongside the launch of KRAZATI™. This program provides support, advice, help and guidance to patients based on their preferences and needs.

The Hub is a centralized location designed to support the execution of our PSP launch strategy.

**Hub Services:**

- Are complimentary for the patients—at no cost to enroll.

- Offer high-touch PSP models for single point of contact to assist along the patient's treatment journey.

- Identify and help reduce potential coverage challenges.

- Provide disease and treatment education materials to ensure dosage and persistency recommendations.

- Connect patient/caregivers to other advocacy and community support services.

Separately, Mirati has an Expanded Access Program for KRAZATI™ in the United States for the treatment of eligible people with KRASG12C-mutated cancers, regardless of tumor type. Find more about this program at [Mirati.com/expanded-access-policy](http://Mirati.com/expanded-access-policy/).
Safety and Quality

The safety of patients in our clinical studies is a company-wide focus. We are committed to the continuous evaluation of the benefits and risks of our investigational products and to taking action to protect the safety and well-being of those taking our therapies. We apply the highest ethical, scientific and clinical standards in all our scientific research.

Our Quality and Safety Policies start and end with patient safety throughout the product life cycle. We are dedicated to rigorous compliance with all laws and regulations regarding quality, safety and performance requirements. We set high standards and focus on achieving continuous improvement in our quality processes.

Our Senior Vice President of Pharmacovigilance & Chief Safety Officer has responsibility for Mirati’s product quality and safety. Ultimate quality management oversight lies with our ELT and our BoD, which receive regular updates on our quality procedures and performance.

Our Quality Management System (QMS) guides our product and safety quality processes. We have developed standard operating procedures (SOPs) to ensure product quality and patient safety. Additionally, our quality management review program includes regular internal and external safety audits. We have set stringent product quality metrics that we monitor for conformance and investigate any incidents.

Our Pharmacovigilance and Safety (PV & Safety) Risk Management function consists of physicians, pharmacists, nurses and other trained professionals who manage the collection, monitoring, evaluation and reporting of safety information. This function conducts ongoing assessment of the safety risk profile of our investigational medicines throughout all stages of product development. The PV & Safety system ensures that we maintain compliance with the legal requirements for pharmacovigilance tasks and responsibilities, as these govern, define and regulate obligations and activities.

To ensure safety, we have extensive emergency response processes in place. As part of our QMS, we maintain a dedicated Corrective and Preventive Action program, which states the incident investigation and corrective action procedures in the event of a product safety complaint or event. Further, we are committed to public reporting on product issues, as required by law. Potential safety concerns are communicated to researchers, participants and regulators in compliance with U.S. Food and Drug Administration (FDA) regulations, International Council for Harmonization guidelines and global industry Good Vigilance Practice. All pharmacovigilance activities are conducted under strict internal SOPs or those of our contracted partners.

All employees in Pharmacovigilance and Safety Risk Management undertake regular training on pharmacovigilance processes, including SOPs and according to internationally recognized Good Laboratory Practice, Good Manufacturing Practice, Good Distribution Practice, Good Clinical Practice and Good Pharmacovigilance Practice standards.

All products and services undergo stringent regulatory and self-evaluation safety risk assessments to meet our extensive quality requirements. We proactively conduct risk assessments on every product throughout the entirety of its life cycle. Tools are developed and implemented to minimize product risks, while preserving the benefits of the product. As an added measure to ensure patient safety, we also monitor the quality of the safety work done by our partners and confirm adherence to regulations and guidelines. Further, we work with regulators to identify, mitigate and communicate any potential risks.

Drug Promotion and Ethical Marketing

Through our ethical, scientific and safety standards we set a high bar, and we comply with all laws, guidelines and industry codes at all times. The quality and safety of our products are paramount to our reputation, and we hold the same stringent standard for the promotion of our drugs.

Our Safety Management Team is responsible for promoting the safe and effective use of medicinal products, through providing timely information about the benefits and risks of medicinal products to patients, HCPs and
the public. Specifically, the Safety Management Team updates reference safety information, such as product labels, as well as the addition of confirmed safety signal and associated risks in the product label. Our Head of Regulatory Affairs & Quality Assurance is responsible for an effective Global Labeling Governance System. Additionally, our Promotional Review Team Committee, composed of medical, legal and regulatory personnel, reviews and approves all external marketing documents.

Mirati has established mandatory standards that all employees, consultants, contract workers and temporary employees must follow when interacting with HCPs and other customers. We maintain collaborative relationships with HCPs where appropriate to inform the medical community and patients about our products and provide relevant scientific and educational information to support patient care and the practice of medicine. In addition to requiring that all interactions with HCPs and other customers comply with applicable laws, we seek to ensure that our interactions with HCPs consistently meet or exceed industry guidelines. Additionally, all expense reimbursements paid to HCPs are submitted for review and approval to Mirati’s Compliance department to ensure compliance with our policies. All payments made to HCPs are disclosed as required at the U.S. federal, state and local level, as well as in compliance with other national reporting requirements where we operate.

All employees receive annual training on promotional standards. To ensure compliance and adherence to our Healthcare Compliance policy, we conduct periodic reviews and internal audits. Any identified issues or incidents are investigated until resolution.

Clinical Trial Standards

At Mirati, we are committed to conduct trials in an ethical manner. We have established a series of policies and procedures that govern and describe the ethics of conducting clinical trials, including topics such as obtaining patient’s prior informed consent and respect for potential and enrolled subjects, as well as fair subject selection, among others.

We adhere to international best practice guidelines, including Good Clinical Practice (GCP) Guidance for designing, conducting, recording and reporting trials. GCP is an international ethical and scientific quality standard that is provided by the International Council on Harmonization. Compliance with this standard provides public assurance that the rights, safety and well-being of trial subjects are protected and that the clinical trial data are credible.

Our management team has responsibility for ethical conduct of our trials. Additionally, for each clinical study executed, a master Informed Consent Form (ICF) template is required and is submitted to a central Institutional Review Board (IRB) for approval before adoption. The ICF template provides information regarding the rights of trial subjects and includes relevant contact information in the event of a concern or complaint. Each clinical trial must be reviewed and approved by an IRB or ethics committee. An IRB or ethics committee monitors our trial’s ethics and has the authority to approve, modify or stop trials. Independent ethics committees and IRBs review and approve essential clinical trial documents, such as protocols and ICFs, which include the relevant contact information in the event of a concern or complaint, before they are implemented.

Our Safety Management team evaluates benefit to risk assessments to ensure that safety data are appropriately monitored and evaluated to assess risk of products, as well as to decide recommended actions and communications to meet regulatory requirements.

Our Safety Management Team monitors safety data across all study participants to identify potential issues or concerns, which are handled in accordance with our study plans.

All employees in our clinical development organization are required to take a clinical trials ethics overview course and undertake GCP training.

All clinical trials have prior registration in credible and publicly available databases, including ClinicalTrials.gov. We are committed to following trial requirements when publishing trial results.
Manufacturing Quality

We currently do not own or operate manufacturing facilities for the production of any of our product candidates, nor do we plan to develop our own manufacturing operations in the foreseeable future. We currently partner with third-party contract manufacturers for all of our required raw materials and finished products for our preclinical and clinical trials.

Manufacturers of our investigational candidates are required to comply with applicable FDA manufacturing requirements contained in the FDA’s Current Good Manufacturing Practices (cGMP) regulations. The cGMP regulations require, among other things, quality control and quality assurance, as well as corresponding maintenance of records and documentation.

Supply Chain Governance

Mirati maintains a rigorous standard for quality, and we uphold the same standard across our supply chain. When introducing vendors to our supply chain, we focus on assuring the GxP compliance of vendor systems, processes and operations. Vendor selection, management and due diligence are included in our quality risk management process. As part of our commitment to diversity, we include questions regarding supplier diversity as part of our Request for Proposal process.

We manage business conduct and ethics in our supply chain through providing a Supplier Code of Conduct that outlines standards of behavior for our suppliers. To ensure security and minimize risk in our supply chain, we maintain security requirements that are part of the Commercial Manufacturing and Supply Agreement for Contract Manufacturing Organizations. All employees and sub-contractors are required to be trained in security and threat awareness. Individual security responsibilities and immediate actions are to be taken in the event of any security-related incident. Our ELT oversees quality in our supply chain.
Environment

At Mirati, we are committed to operating responsibly and sustainably, and we strive to minimize our emissions and efficiently use resources at our facilities.

Our ELT, with oversight from the BoD, oversees environmental programs and policies at Mirati, including our environmental management system, which ensures we comply with relevant regulations. The Nominating and Corporate Governance Committee manages environmental matters, and it reviews environmental policies and programs to ensure we are operating at the highest standards of corporate social responsibility.

As part of our environmental program, we conduct regular environmental impact assessments. We do not own or operate our own manufacturing facilities, and, instead, we rely on third-party contract manufacturers to supply the required raw materials and finished products. We recognize the importance of emission and waste reduction. Our preclinical research, manufacturing and development processes involve the controlled use of hazardous and radioactive materials. We are subject to federal, local and foreign laws and regulations governing the use, manufacture, storage, handling and disposal of such materials and certain waste products. Additionally, we track biological and hazardous waste from research and development. All our hazardous waste is treated properly by a third-party vendor.

Additionally, we have integrated electric vehicle (EV) chargers at our campus. We are proud to have implemented chargers to facilitate the use of EVs at Mirati.
Mirati is committed to operating at the highest standard of ethical behavior in everything we do. The BoD has delegated oversight of business ethics to the Audit Committee of the BoD. Our General Counsel provides day-to-day oversight and management of our ethics and compliance program.

We are guided by our Code of Business Conduct and Ethics (Code of Conduct) which applies to all officers, directors and employees. In addition, our Employee Handbook helps employees understand our critical employee policies, while our Healthcare Compliance handbook helps employees plan and execute our commercial and business strategies using a compliant approach.

**Anti-Bribery and Anti-Corruption**

We strive to foster an environment free of bribery and corruption wherever we operate in the world. In addition to business practices and principles of behavior that support our commitment to operate at the highest standards of business conduct and ethics, the Code of Conduct also includes definitions and policies on gifting, entertainment and related anti-bribery and anti-corruption measures. Unless express permission is received in advance from a supervisor, the Compliance Officer or the Audit Committee, Mirati employees are prohibited to offer, provide or accept any gifts or entertainment, even where such practices are considered “a way of doing business.” In the case where express permission has been granted, Mirati strictly prohibits offering, providing or accepting extravagant or excessive gifts and entertainment.

Each Mirati employee is required to annually receive training and review and acknowledge the (i) the Code of Conduct, (ii) the Employee Handbook, (iii) the Healthcare Compliance Handbook, (iv) insider trading and (v) anti-harassment modules through interactive, web-based courses. All employees also receive annual training on data security awareness, which requires complete signoff of both the Business Code of Conduct & Ethics and Electronics Resources policies. Records of completion are maintained as part of internal and external audits. Further, all employees receive training on Mirati’s social media policy.

**Whistleblower Program**

Mirati is committed to providing a workplace conducive to open discussion of our business practices and is committed to address major business ethics risks. As such, we have in place a procedure for employees and all stakeholders to anonymously report complaints through our independent, 24/7 Compliance Hotline (hotline), our compliance web portal or via regular mail to our Compliance Officer.

The Compliance Officer, under the direction and oversight of the Audit Committee, administers and oversees our Whistleblower Program and Open Door Policy for Reporting Complaints Regarding Accounting Matters. Embedded in our procedure and Open Door Policy for Reporting Complaints Regarding Accounting Matters is also our Policy of Non-Retaliation that covers all Mirati employees and those of our subsidiaries. Upon receiving a complaint, the Compliance Officer determines whether the information pertains to an accounting matter and if both the CEO and the Chair of the Audit Committee should be notified. Throughout the reporting and investigation process, the Compliance Officer maintains the reporter’s confidentiality and records all communications. All complaints received are tracked and investigated until resolved. To actively deter non-compliance and reduce exposure to unethical opportunities, we communicate our hotline through our Code of Business Conduct and Ethics and through its annual training to all employees.
IT and Information Security

Our information and the information of our clients are extremely valuable, and the safekeeping of that information is of utmost importance to us. We have in place an Information Security Policy (ISP), which is designed to primarily evaluate and safeguard the electronic and physical methods of accessing, collecting, storing, using, transmitting and protecting Personally Identifiable Information, Personal Health Information, Health Authority Regulated data and any other confidential and regulated information. We conduct annual internal control audits and external audits on an ad-hoc basis. Our Vice President of Information Technology is responsible for the annual internal audit process. Following which, the result of the annual internal audit is shared with our ELT to foster a continuous improvement process. The ISP is aligned with ISO/IEC 27002:2013 industry standard. All employees receive annual training on the ISP and must sign acknowledgement of our Electronic Resources policies.

Intellectual Property

As a commercial-stage biopharmaceuticals company, intellectual property is a highly valued, intangible asset to us. We believe the ability to achieve our strategic and operational objectives largely depends on how successful we are in developing and protecting our intellectual property assets. We have in place an Intellectual Property Policy which applies to all intellectual property rights owned and/or licensed by the Company, and further addresses the Company's compliance with applicable intellectual property laws. All employees receive regular mandatory training on this policy. In addition, Mirati's consultants, advisors and contractors receive ad-hoc training as determined by our Intellectual Property department.
### Appendix

#### Sustainability Accounting Standards Board (SASB) Index

The following table provides data and information for Mirati utilizing the SASB’s Biotechnology & Pharmaceuticals industry standard.

<table>
<thead>
<tr>
<th>Accounting Metric</th>
<th>Code</th>
<th>Information</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Safety of Clinical Trial Participants</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Discussion, by world region, of management process for ensuring quality and patient safety during clinical trials</td>
<td>HC-BP-210a.1</td>
<td>For details, see Clinical Trial Standards in the Safety &amp; Quality section of this report.</td>
</tr>
<tr>
<td>Number of FDA Sponsor Inspections related to clinical trial management and pharmacovigilance that resulted in: (1) Voluntary Action Indicated (VAI) and (2) Official Action Indicated (OAI)</td>
<td>HC-BP-210a.2</td>
<td>All data report to relevant national regulators.</td>
</tr>
<tr>
<td>Total amount of monetary losses as a result of legal proceedings associated with clinical trials in developing countries</td>
<td>HC-BP-210a.3</td>
<td>Not applicable.</td>
</tr>
<tr>
<td><strong>Access to Medicines</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Description of actions and initiatives to promote access to health care products for priority diseases and in priority countries as defined by the Access to Medicine Index</td>
<td>HC-BP-240a.1</td>
<td>For details, see the Patients and Access to Medicine section of this report.</td>
</tr>
<tr>
<td>List of products on the WHO List of Prequalified Medicinal Products as part of its Prequalification of Medicines Programme (PQP)</td>
<td>HC-BP-240a.2</td>
<td>No Mirati products are on the WHO List at the time of reporting.</td>
</tr>
<tr>
<td><strong>Affordability &amp; Pricing</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Number of settlements of Abbreviated New Drug Application (ANDA) litigation that involved payments and/or provisions to delay bringing an authorized generic product to market for a defined time period</td>
<td>HC-BP-240b.1</td>
<td>Not applicable.</td>
</tr>
<tr>
<td>Percentage change in: (1) average list price and (2) average net price across U.S. product portfolio compared to previous year</td>
<td>HC-BP-240b.2</td>
<td>Not applicable.</td>
</tr>
<tr>
<td>Percentage change in: (1) list price and (2) net price of product with largest increase compared to previous year</td>
<td>HC-BP-240b.3</td>
<td>Not applicable.</td>
</tr>
<tr>
<td><strong>Drug Safety</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>List of products listed in the Food and Drug Administration’s (FDA) MedWatch Safety Alerts for Human Medical Products database</td>
<td>HC-BP-250a.1</td>
<td>There were no Mirati products listed on U.S. FDA MedWatch at the time of reporting.</td>
</tr>
<tr>
<td>Number of fatalities associated with products as reported in the FDA Adverse Event Reporting System</td>
<td>HC-BP-250a.2</td>
<td>There were no fatalities associated with Mirati commercial products listed on U.S. FDA Adverse Event Reporting System (FAERS) Public Dashboard at the time of reporting. Please reference safety statistics in KRAZATI label.</td>
</tr>
<tr>
<td>Number of recalls issued, total units recalled</td>
<td>HC-BP-250a.3</td>
<td>Mirati has not issued any recalls.</td>
</tr>
<tr>
<td>Total amount of product accepted for takeback, reuse, or disposal</td>
<td>HC-BP-250a.4</td>
<td>Not reported.</td>
</tr>
<tr>
<td>Number of FDA enforcement actions taken in response to violations of current Good Manufacturing Practices (cGMP), by type</td>
<td>HC-BP-250a.5</td>
<td>No FDA enforcement actions taken in 2021 or 2022 in response to violations of current Good Manufacturing Practices (cGMP).</td>
</tr>
<tr>
<td><strong>Counterfeit Drugs</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Description of methods and technologies used to maintain traceability of products throughout the supply chain and prevent counterfeiting</td>
<td>HC-BP-260a.1</td>
<td>For details, see Safety and Quality section of this report.</td>
</tr>
<tr>
<td>Category</td>
<td>Description</td>
<td>Code</td>
</tr>
<tr>
<td>----------</td>
<td>-------------</td>
<td>------</td>
</tr>
<tr>
<td>Ethical Marketing</td>
<td>Discussion of process for alerting customers and business partners of potential or known risks associated with counterfeit products</td>
<td>HC-BP-260.a.2</td>
</tr>
<tr>
<td></td>
<td>Number of actions that led to raids, seizure, arrests, and/or filing of criminal charges related to counterfeit products</td>
<td>HC-BP-260.a.3</td>
</tr>
<tr>
<td>Employee Recruitment, Development &amp; Retention</td>
<td>Total amount of monetary losses as a result of legal proceedings associated with false marketing claims</td>
<td>HC-BP-270.a.1</td>
</tr>
<tr>
<td></td>
<td>Description of code of ethics governing promotion of off-label use of products</td>
<td>HC-BP-270.a.2</td>
</tr>
<tr>
<td>Supply Chain Management</td>
<td>Percentage of (1) entity’s facilities and (2) Tier I suppliers’ facilities participating in the Rx-360 International Pharmaceutical Supply Chain Consortium audit program or equivalent third-party audit programs for integrity of supply chain and ingredients</td>
<td>HC-BP-430.a.1</td>
</tr>
<tr>
<td>Business Ethics</td>
<td>Total amount of monetary losses as a result of legal proceedings associated with corruption and bribery</td>
<td>HC-BP-510.a.1</td>
</tr>
<tr>
<td></td>
<td>Description of code of ethics governing interactions with health care professionals</td>
<td>HC-BP-510.a.2</td>
</tr>
<tr>
<td>Activity Metrics</td>
<td>Number of patients treated</td>
<td>HC-BP-000.a</td>
</tr>
<tr>
<td></td>
<td>Number of drugs (1) in portfolio and (2) in research and development (Phases 1-3)</td>
<td>HC-BP-000.b</td>
</tr>
</tbody>
</table>
Task Force on Climate-related Financial Disclosures (TCFD) Index

Mirati Therapeutics acknowledges climate-related initiatives and their importance. We are committed to providing transparency on our climate change-related risk management. A summary of our response to the Task Force on Climate-related Financial Disclosures (TCFD)-recommended disclosures is below.

Governance

Board Oversight: Mirati’s BoD is committed to presume an active role in sustainability, especially in conjunction with our overall business strategy and risk management. The Nominating and Corporate Governance committee provides oversight of Mirati’s environmental initiatives, programs, policies and strategies, including those related to climate change. The Audit Committee reviews risks published in our Annual Report, including those related to climate change.

Management Oversight: Our ELT, including our CEO, subject to oversight by our BoD, structures, monitors and adjusts corporate sustainability in a manner that is consistent with our core values and in a manner that best serves the interests of Mirati and our stakeholders. The ELT reports to the BoD on Mirati’s corporate sustainability.

Strategy

Mirati is a biopharmaceutical company, and we consider our products climate-resilient and therefore do not consider climate-related risks as material at this time. However, Mirati regularly assesses climate change and its related risks and how they might influence our operations. We view the potential of business disruption from extreme weather and natural disasters as a result of climate change seriously.

Risk Management

Mirati’s ELT and BoD are focused on managing and mitigating various risks to our business and financial performance, including climate change and other environmental risks. We employ a cross-organizational approach to identify, assess, review and mitigate such risk. Risk management is a subject reported to and discussed at BoD meetings regularly. Our Audit Committee reviews and discusses with management Mirati’s guidelines and policies with respect to risk assessment and risk management, including the Company’s major financial and risk exposures and the steps taken by management to monitor and control these exposures. The Audit Committee also oversees the risk factors disclosed in our Annual Report.

Metrics

We are currently reviewing our disclosure of carbon emissions.